Your browser doesn't support javascript.
Radiothérapie des oligométastases : principaux essais en cours et à venir en France. / [Stereotactic body radiotherapy of oligometastases: Main pending trials and to come in France].
Cancer Radiother ; 23(6-7): 496-499, 2019 Oct.
Artigo em Francês | MEDLINE | ID: mdl-31471251
Stereotactic radiotherapy of oligometastases, mono- or hypofractionated, represents a fundamental change in the practice of the specialty as it was developed for a century. Despite the great heterogeneity of sites, techniques, and doses, most studies found a high local control rate, around 70 to 90% at 2 years, and reduced toxicity, around 5% of grade 3 at 2 years. Four main phase II and III trials are underway in France. Future research concerns the association of stereotactic radiotherapy with immunotherapy or different conventional chemotherapy protocols, the identification of the best clinical presentations, and optimization of fractionation and biological dose for poor prognosis localizations.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Radiocirurgia / Ensaios Clínicos Fase III como Assunto / Ensaios Clínicos Fase II como Assunto / Neoplasias Aspecto clínico: Predição / Prognóstico / Terapia Limite: Humanos / Masculino País/Região como assunto: Europa Idioma: Francês Revista: Cancer Radiother Assunto da revista: Neoplasias / Radioterapia Ano de publicação: 2019 Tipo de documento: Artigo